Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

504 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-01

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute adhesive Small Bowel Obstruction (ASBO) is a public health issue: this is the 3rd cause of hospitalization in Digestive Surgery Departments, 20-30% of patients will be operated, the mortality rate per episode is 3%, the duration of hospitalization is 8 days (up to 16 if resection), and it is associated with a tremendous health care expenses.

The working group on ASBO of the World Society of Emergency Surgery suggested two distinct approaches for the management of acute ASBO: non-operative management (NOM) which concerning around 85% of patients and operative management (OM) :

* OM: if there is clinical signs of strangulation, peritonitis, bowel ischemia, or if IV CT Scan shows sign of ischemia, strangulation, peritonitis, or if the occlusion persists for more than 72 hours;
* NOM in all other cases, including nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.

NGT is an old concept first describe for treatment of ASBO based on several studies made on the dog where he proved efficacy of NGT by aspirating gas in the stomach favorising venous decompression and survival of patients. Since, NGT became one of the pillars of NOM.

However NGT is quite bad tolerated by patients (ranked the most painful hospital procedure), some of them refuse it, others put off after the beginning of the treatment and one of the most frequent complications of NGT is pneumonia, which is quite surprising when the first argument for its insertion is to avoid inhalation pneumonia.

Four specific retrospectives studies showed that absence of NGT is possible in 20 to 80% of included patients and was associated with a decrease: in transit recovery time; in complications rate (including rates of pneumonia); in length of stay (LOS); without an increased risk of surgery or resection. 20-87% (a total of 922 patients) were managed successfully conservatively without NGT with a reduction LOS of 2-6 days compared with NGT. But none of this series focused on the patient relief as an endpoint. A retrospective critical analysis of our own management (January - December 2019, n=96) found that: only 17% of patients had a NGT during the IV CTscan, the presence of the NGT did not influence neither gastric volume nor the rate of full stomach, and gastric volume did not influence patient management.

To summarize, the investigators therefore know that the insertion of a NGT is painful, does not relieve all patients, and has an unquantified therapeutic effect on the evolution of ASBO. That is why it is pertinent, in 2023, to question the useless of NGT in the treatment of ASBO, in selected patients. This study would be the first randomized controlled trial to focus on the absence of NGT for the NOM of patients with ASBO. The results of this study could lead to a change in the surgical practice. The absence of NGT in ASBO management appears to be an innovative practice, in rupture with the current practice. This is a part of the simplification of patients'care suffering from ASBO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimizing Treatment of Adhesive Small Bowel Obstruction

NCT06182319

Adhesive Small Bowel Obstruction

RECRUITING PHASE3

Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement

NCT02530086

Small Bowel Obstruction

WITHDRAWN NA

Endoscopic Gastroenteric Anastomosis With New Tissue Apposing Stent in the Management of Antro-pyloroduodenal Obstruction : Evaluation of Feasibility, Efficacy and Tolerance.

NCT02562157

Antro-pyloric and/or Duodenal Benign or Malignant Obstructions

COMPLETED NA

Novel Motorized Spiral Enteroscopy Vs Single Balloon Enteroscopy In Patients With Small Bowel Disorders- A RCT

NCT05548140

Small Bowel Disease

COMPLETED NA

Contribution of Point of Care Ultrasound by the Emergency Physician to Rule Out the Small Bowel Obstruction: a Diagnostic, Multicenter Study

NCT06803628

Small Bowel Obstruction

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Small Bowel Obstruction Adhesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group (NGT+ group)

Patients treated with standard NOM (NGT, intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h)

Group Type ACTIVE_COMPARATOR

nasogastric tube

Intervention Type PROCEDURE

nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.

Experimental group (NGT- group)

Patients treated with NOM without NGT insertion (intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h)

Group Type EXPERIMENTAL

NOM without NGT insertion

Intervention Type OTHER

intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nasogastric tube

nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.

Intervention Type PROCEDURE

NOM without NGT insertion

intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of an obstruction believed to be secondary to adhesions (abdominal pain and distention, nausea and/or vomiting, no gas and/or stool).
* Uncomplicated presentation (no signs of strangulation or peritonitis).
* IV CT scan of the abdomen consistent with an uncomplicated ASBO, (performed with a pillow to raise slightly the patient.
* Aged 18 or older.
* Provision of written, informed consent.
* Patient covered by French national health insurance.

Exclusion Criteria

* An incarcerated and/or strangulated incisional hernia, colonic obstruction.
* No previous abdominal operation.
* Obstruction within 4 weeks after a recent operation.
* Gastrointestinal neoplasm in progress.
* Inflammatory bowel disease in progress.
* Abdominal radiotherapy in the last 6 months.
* Contraindication to intravenous contrast enhancement for the CT scan, pre-existing risks factors for pneumonitis.
* Antecedent of aspiration pneumonia.
* Age \> 85 years.
* Orientation disturbance.
* Bedridden.
* Chronic cerebrovascular disease (cerebral infarction sequelae, Parkinson disease etc).
* Dementia.
* Gastroesophageal disorder (gastroesophageal reflux)
* Pregnancy or breastfeeding.
* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision).
* Patients unable to provide informed consent.
* Age \<18 years.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No